Innovation Pharmaceuticals Inc. - 10-Q filing on 2020-02-13

Equity Transaction (Details Narrative) - USD ($)							1 Months Ended								6 Months Ended
Equity Transaction (Details Narrative) - USD ($)	Jan. 01, 2020	May 09, 2019	Nov. 12, 2018	Oct. 12, 2018	Oct. 05, 2018	Sep. 06, 2017	Dec. 26, 2019	May 10, 2019	May 10, 2019	May 09, 2019	Oct. 09, 2018	Oct. 05, 2018	Jun. 28, 2018	Mar. 30, 2015	Dec. 31, 2019	Dec. 30, 2019	Dec. 31, 2018	Sep. 30, 2019	Jun. 30, 2019	Jan. 29, 2019	Sep. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Proceeds from warrant exercises															$ 1,253,000
Conversion of Series B Convertible Preferred stock to Common stock, reversed															3,068,000
Amount of series B preferred stock dividends paid															17,000
Proceeds from issuance of shares															1,116,000
5% accrued dividend															$ 42,000
Beginning balance, Shares
Preferred stock, shares outstanding (in shares)															0				0			0
Conversion of preferred stock to common stock description															The two preferred stockholders converted 1,181 shares of Series B preferred stock into 15.0 million shares of common stock. As of December 31, 2019, 1,440 shares of Series B 5% convertible preferred stock were outstanding.
Share price		$ 535.12								$ 535.12									$ 535.12
Proceeds from warrant exercises															$ 1,152,000
Warrant [Member]
Preferred stock, shares outstanding (in shares)															7,720							0
Stock issuance cost															$ 32,000
Common Class B [Member]
Common stock, share outstanding															909,090				909,090
Common Class B [Member] \| Leo Ehrlich [Member]
Share price																				$ 0.11
Common stock shares issued upon extinguishment of debt																				909,090
Amount of debt extinguished																				$ 100,000
Common stock, share outstanding															909,090				909,090
Series B [Member]
Proceeds from warrant exercises					$ 2,700,000							$ 2,700,000
Stock issued during period, shares
Series B [Member] \| Series 1-2 warrants [Member]
Rights and preferences of the preferred stock description					Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance							Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance
Proceeds from warrant exercises			$ 245,625	$ 300,000	$ 2,730,000						$ 500,000				$ 1,200,000
Exercised															1,192
Purchase shares of Series B preferred stock															6,528
Series B [Member] \| Series 1-3 warrants [Member]
Purchase of warrants															7,720							8,000,000
Series B Convertible Preferred Stock [Member] \| Subsequent Event [Member]
Conversion of Series B Convertible Preferred stock to Common stock, reversed															$ 294,000
Amount of series B preferred stock dividends paid																$ 24,000
5% accrued dividend															$ 17,000
Preferred stock, shares outstanding (in shares)															1,027							0
Proceeds from warrant exercises	$ 255,000		$ 245,625	$ 300,000	$ 2,730,000						$ 500,000				$ 1,000,000
5% accrued dividend															$ 21,000	$ 41,000
Number of warrants exercised					2,780							2,780			1,045
Exercised															1,045
Purchase shares of Series B preferred stock															6,675
Stock issued during period, shares				750	2,780						1,250
Stock issued during period, value				$ 400,000							$ 700,000
Beneficial conversion feature				700,000							1,200,000
Stock issuance cost															$ 41,000
Change in fair value of preferred stock liabilities															102,000
Loss due to change in fair value of preferred stock															$ 63,000
Common Class A [Member]
Common stock, share outstanding															218,551,663				202,631,923
Beginning balance, Shares															187,575,318							163,103,927
June 30, 2019 [Member]
Conversion of preferred stock to common stock description															the two preferred stockholders converted 3,891 shares of Series B preferred stock into 39.2 million shares of common stock
On June 28, 2018 [Member] \| Warrant [Member]
Proceeds from issuance of shares					$ 2,000,000							$ 2,000,000
Beginning balance, Shares					2,000							2,000
Rights and preferences of the preferred stock description
Stock issued description					An initial closing for the sale of 1,250 shares of preferred stock closed on October 9, 2018, and a subsequent closing for the sale
Warrants to purchase additional shares					8,000
Conversion cap limits description					The conversion cap limits conversions by the holders to the greater of $75,000 and an amount equal to 30% of the aggregate dollar trading volume of the Company’s common stock for the five trading days immediately preceding, and including, the conversion date.
Purchase of warrants															8,000,000							8,000,000
On September 1, 2018 [Member]
Proceeds from issuance of shares															$ 1,116,000
5% accrued dividend															$ 25,000
On September 1, 2018 [Member] \| Ms. Anne Ponugoti [Member]
Conversion of preferred stock to common stock description								In addition, there were 375 preferred stock shares converted to 4,557,103 common stock.
Proceeds from warrant exercises								$ 540,000	$ 540,000
On September 1, 2018 [Member] \| Ms. Jane Harness [Member]
Rights and preferences of the preferred stock description												Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance (later extended to 15 months following issuance)
On September 1, 2018 [Member] \| Ms. Jane Harness [Member]
Rights and preferences of the preferred stock description					Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance (later extended to 15 months following issuance)
Warrants exercised description
Warrant Amendment Agreement [Member]
Exercise price description							Adjust the exercise price of each warrant from $982.50 to $850.00 per share of Series B preferred stock.
Modification expense							$ 1,212,000
Share price							$ 0.05
Securities Purchase Agreement [Member] \| Aspire Capital Fund LLC [Member] \| Stock And Warrant [Member]
Stock issued during period, shares													8,000,000
Beneficial conversion feature													$ 700,000
Securities Purchase Agreement [Member] \| Series B [Member]
Purchase of warrants																						7,720
Securities Purchase Agreement [Member] \| Series B [Member] \| Series 4 warrant [Member]
Proceeds from issuance of shares		$ 2,000,000								$ 2,000,000
Rights and preferences of the preferred stock description		The Series 4 warrant entitles the holder thereof to purchase 2,500 shares of preferred stock at $982.50 per share for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance. In addition, the Company extended the termination date for the Series 1 warrants by six months, and agreed to issue one additional share of preferred stock to the Series B investors for each five shares issued upon the exercise of the existing warrants or Series 4 warrants through November 9, 2019, up to a maximum of 400 shares of preferred stock.								The Series 4 warrant entitles the holder thereof to purchase 2,500 shares of preferred stock at $982.50 per share for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance. In addition, the Company extended the termination date for the Series 1 warrants by six months, and agreed to issue one additional share of preferred stock to the Series B investors for each five shares issued upon the exercise of the existing warrants or Series 4 warrants through November 9, 2019, up to a maximum of 400 shares of preferred stock.
Securities Purchase Agreement [Member] \| Series B [Member] \| Series 1 warrant [Member]
Rights and preferences of the preferred stock description					Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance							Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance
Terms of agreement		the Company issued an additional 100 shares of Series B preferred stock and Series 4 warrants to purchase an additional 2,500 shares of preferred stock, and the holders of the Series B preferred stock and warrants agreed to exercise warrants to purchase up to $2.0 million of Series B preferred stock through November 2019 subject to the conditions set forth in the Issuance Agreement. The Series 4 warrant entitles the holder thereof to purchase 2,500 shares of preferred stock at $982.50 per share for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance. In addition, the Company extended the termination date for the Series 1 warrants by six months, and agreed to issue one additional share of preferred stock to the Series B investors for each five shares issued upon the exercise of the existing warrants or Series 4 warrants through November 9, 2019, up to a maximum of 400 shares of preferred stock
Securities Purchase Agreement [Member] \| Series B [Member] \| Series 2 warrant [Member]
Rights and preferences of the preferred stock description					Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance							Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance
Terms of agreement		the Series B investors have agreed, subject to the conditions set forth therein, to exercise existing warrants to purchase 500 shares of preferred stock and to amend the existing warrants to permit the Company to compel the exercise of up to $400,000 of existing warrants each calendar month commencing June 3, 2019 and ending November 1, 2019, or, if earlier, until the aggregate amount of the forced exercises is $2,000,000. As consideration for the Series B investors entering into the Issuance Agreement, the Company has issued 100 shares of preferred stock and warrants to purchase 2,500 shares of preferred stock (“Series 4 warrants”) to the Series B investors. In addition, the Company extended the termination date for the Series 1 warrants issued in October 2018 by six months, and has agreed to issue one additional share of preferred stock to the Series B investors for each five shares issued upon the exercise of the existing warrants or Series 4 warrants through November 9, 2019, up to a maximum of 400 shares of preferred stock
Securities Purchase Agreement [Member] \| Series 1-4 [Member] \| Series 3 warrant [Member]
Preferred stock, shares outstanding (in shares)															1,196
Rights and preferences of the preferred stock description					Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance							Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance
Proceeds from warrant exercises															$ 1,152,000
Securities Purchase Agreement [Member] \| On June 28, 2018 [Member] \| Common Class A [Member] \| Aspire Capital Fund LLC [Member]
Rights and preferences of the preferred stock description					Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance							Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance
30 Million Common Stock Purchase Agreement [Member] \| Common Class A [Member] \| Aspire Capital Fund LLC [Member]
Stock issued during period, shares						300,000								160,000